| HIV-HBV Coinfection (n = 7) | HBV Monoinfection (n = 118) | P value |
---|---|---|---|
Age (year) (median (IQR)) | 52(46–61) | 48.5 (35–55) | 0.323 |
Male (n (%)) | 7(100%) | 103 (87.29%) | 0.315 |
Indication (n (%)) | Â | Â | Â |
Liver failure | 6(85.7%) | 73(61.86%) | 0.204 |
Decompensated liver cirrhosis | 1(14.3%) | 45(38.14%) | |
Detectable HBV DNA pre-OLT (n (%)) | 4(57.1%) | 101(85.59%) | 0.046 |
MELD score (median (IQR)) | 34(31–40) | 31(18-39.25) | 0.544 |
CD4 cell count pre-OLT (cells/ul) (median (IQR)) | 121(42–165) | 256.5(146.25–476.5) | 0.006 |
Acute rejection (n (%)) | 1(14.3%) | 5 (4.24%) | 0.227 |
Complications (n (%)) | Â | Â | Â |
Bacteremia | 1(14.3%) | 10 (8.47%) | 0.598 |
CMV infection | 5 (71.43%) | 47(39.83%) | 0.099 |
Pulmonary infection | 2(28.57%) | 34 (28.81%) | 0.989 |
Acute kidney injury | 1(14.3%) | 7(5.93%) | 0.380 |
De novo malignancies | 0 | 2(1.69%) | 0.728 |
Biliary complications | 0 | 6(5.08%) | 0.541 |
Artery complications | 0 | 2 | 0.728 |
Hepatic venous complications | 0 | 1 | 0.807 |
Portal vein thrombosis | 0 | 2(1.69%) | 0.728 |
Length of hospital stay post-OLT (median (IQR)) | 37(31–64) | 26.5 (20.75-35) | 0.092 |
Duration of follow-up after LT (month) | 36(12–39) | 23.5(12.9–33.4) | 0.345 |